Medicinal Products

2726. Deputy Robert Troy asked the Minister for Health the reason the new mandibular device used to treat sleep apnoea is not approved under the drugs payment scheme (details supplied); and whether the new device will be included under the scheme as soon as possible. [41715/25]

2791. Deputy Ken O'Flynn asked the Minister for Health if she will consider reviewing the current regulatory status of melatonin in Ireland, given that it is available over the counter in many EU countries. [41999/25]

2792. Deputy Ken O'Flynn asked the Minister for Health if she will outline the rationale for maintaining prescription-only of melatonin access in this jurisdiction. [42000/25]

2793. Deputy Ken O'Flynn asked the Minister for Health if she will address the significant cost disparity between Irish pharmacy-dispensed melatonin and equivalent products available legally from EU-based manufacturers. [42001/25]

2794. Deputy Ken O'Flynn asked the Minister for Health 1792 the measures, if any, being considered to ensure price transparency, and to protect patients, particularly those with long-term conditions, from excessive mark-ups for essential medications that are not currently covered under public schemes such as the drug payment scheme or the medical card system. [42002/25]

2795. Deputy Aengus Ó Snodaigh asked the Minister for Health the reason octenisan is not included on the general medical scheme for those with medical cards and for whom this product is prescribed. [42003/25]

2882. Deputy Pádraig Rice asked the Minister for Health if her attention has been brought to the exclusion of transgender women from the free HRT scheme (details supplied); if she will re-examine the guidance issued to pharmacies to ensure that transgender women are not excluded from the scheme; and if she will make a statement on the matter. [42566/25]

3019. Deputy Ken O'Flynn asked the Minister for Health if the case of an elderly person (details supplied) will be reviewed who was recently removed from the public health nurse service, which had been providing essential vitamin B12 injections on a three-week cycle. [42857/25]

3023. Deputy Conor Sheehan asked the Minister for Health the action she proposes to take to deal with the unregulated operators in the cosmetics industry; and if she will make a statement on the matter. [42870/25]

3024. Deputy Conor Sheehan asked the Minister for Health if she intends to introduce licensing for non-surgical cosmetic procedures; the form that licensing would take; and if she will make a statement on the matter. [42871/25]

3025. Deputy Conor Sheehan asked the Minister for Health for an update on The Patient Safety (Licensing) Bill 2017, including when the legislation will be referred back to her from the Attorney General’s office; a timeline for enactment; and if she will make a statement on the matter. [42872/25]

3026. Deputy Conor Sheehan asked the Minister for Health if she will update the licensing for the administration of a treatment (details supplied) to allow nurses to administer; and if she will make a statement on the matter. [42873/25]

3078. Deputy Cathal Crowe asked the Minister for Health if a person who has a prescription for medication in one EU country is entitled to use that prescription in another EU state; and if she will make a statement on the matter. [43112/25]

3270. Deputy Dessie Ellis asked the Minister for Health if a drug will be made available to a person (details supplied). [44201/25]

532. Deputy Pádraig O'Sullivan asked the Minister for Health to outline details of any programmes under which the HSE may facilitate access to medicines in emergency circumstances for medicines not on the reimbursement list; and if she will make a statement on the matter. [40320/25]

533. Deputy Pádraig O'Sullivan asked the Minister for Health the anticipated timelines associated with the Programme for Government commitment to explore early access schemes for reimbursement of medicines; and if she will make a statement on the matter. [40321/25]

534. Deputy Pádraig O'Sullivan asked the Minister for Health the total expenditure on new medicines and new uses of existing medicines from January 2025 to 31 May 2025; and if she will make a statement on the matter. [40322/25]

535. Deputy Pádraig O'Sullivan asked the Minister for Health if she is satisfied that all aspects of the reimbursement process are in compliance with the HSE's code of governance; and if she will make a statement on the matter. [40323/25]

233. Deputy Malcolm Byrne asked the Minister for Health the current status of the drug duvyzat-givinostat in Ireland; when a decision could be made to make it available to those with Duchenne muscular dystrophy; and if she will make a statement on the matter. [39799/25]

277. Deputy Naoise Ó Muirí asked the Minister for Health if her attention has been drawn to the proposal that high protein oral nutritional supplements are administered under a managed access programme, the effect this may have on patient well-being and recovery; and if she will make a statement on the matter. [40014/25]

305. Deputy Mairéad Farrell asked the Minister for Health when a person (details supplied) can expect a decision on a recent discretionary hardship application for the purposes of ozempic injections; and if she will make a statement on the matter. [40149/25]

306. Deputy Richard Boyd Barrett asked the Minister for Health whether a prolonged release melatonin drug (details supplied) will be made available in Ireland and covered by the medical card. [40169/25]

855. Deputy Willie O'Dea asked the Minister for Health if tedralan 200mg will be added to the medical card list as this medication is expensive; and if she will make a statement on the matter. [38700/25]

865. Deputy Pádraig Rice asked the Minister for Health the timeline she is working towards to initiate the review of the drug reimbursement process; the patient advocacy representation that will be on the review; and if she will make a statement on the matter. [38733/25]

896. Deputy John McGuinness asked the Minister for Health if the high tech medication repatha will continue to be provided by way of prescription through St. Lukes Hospital, Kilkenny, to patients that are already on the drug prescribed while under the care of the retired consultant (details supplied); if it is the responsibility of St. Lukes, Kilkenny, to resolve the problem and issue a prescripti…